Biophytis SaEURONEXT: ALBPS

Biophytis S A enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia

Jan 28, 2026 at 6:35 AM UTC · Issued by Biophytis SA

28 Jan 2026 07:30 CET

Issuer

BIOPHYTIS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1385091_Press_Release__JointVenture.pdf

Source

Biophytis

Provider

Les Echos

Company Name

BIOPHYTIS

ISIN

FR001400OLP5

Symbol

ALBPS

Market

Euronext Growth

Earlier from Biophytis Sa